NO864993L - 2-((3,5-dihalo-4-aminobenzyl))imidazoliner. - Google Patents

2-((3,5-dihalo-4-aminobenzyl))imidazoliner.

Info

Publication number: NO864993L
Authority: NO; Norway
Prior art keywords: nasal; alpha; product; administration; solution
Prior art date: 1985-12-11

Application number

NO864993A

Other languages

English (en)

Norwegian (no)

Other versions

NO864993D0 (no

Inventor

Martin Winn

John Francis Debernardis

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-12-11

Filing date

1986-12-10

Publication date

1987-06-12

1986-12-10 Application filed by Abbott Lab filed Critical Abbott Lab

1986-12-10 Publication of NO864993D0 publication Critical patent/NO864993D0/no

1987-06-12 Publication of NO864993L publication Critical patent/NO864993L/no

Links

MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 25
238000000034 method Methods 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 5
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
239000000047 product Substances 0.000 description 21
239000000203 mixture Substances 0.000 description 18
210000001519 tissue Anatomy 0.000 description 17
239000000243 solution Substances 0.000 description 15
230000000694 effects Effects 0.000 description 14
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 10
229960002748 norepinephrine Drugs 0.000 description 10
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 10
WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
239000002552 dosage form Substances 0.000 description 8
210000002850 nasal mucosa Anatomy 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
239000000556 agonist Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
206010028735 Nasal congestion Diseases 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
231100000673 dose–response relationship Toxicity 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
244000025254 Cannabis sativa Species 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000133 nasal decongestant Substances 0.000 description 5
229960001528 oxymetazoline Drugs 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
208000027744 congestion Diseases 0.000 description 4
230000008602 contraction Effects 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000003928 nasal cavity Anatomy 0.000 description 4
229960003418 phenoxybenzamine Drugs 0.000 description 4
239000007921 spray Substances 0.000 description 4
UFQDKRWQSFLPQY-UHFFFAOYSA-N 4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound Cl.C1CN=CN1 UFQDKRWQSFLPQY-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
239000000850 decongestant Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
-1 hydrochloric Chemical class 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
230000001242 postsynaptic effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
QWUSDUYJDKJFKK-UHFFFAOYSA-N (4-amino-3,5-dichlorophenyl)methanol Chemical compound NC1=C(Cl)C=C(CO)C=C1Cl QWUSDUYJDKJFKK-UHFFFAOYSA-N 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
229940086681 4-aminobenzoate Drugs 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010052437 Nasal discomfort Diseases 0.000 description 2
230000010799 Receptor Interactions Effects 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960003920 cocaine Drugs 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000011067 equilibration Methods 0.000 description 2
229950006240 hydrocortisone succinate Drugs 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000003518 presynaptic effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
210000001147 pulmonary artery Anatomy 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
108060003345 Adrenergic Receptor Proteins 0.000 description 1
102000017910 Adrenergic receptor Human genes 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
206010049153 Allergic sinusitis Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033557 Palpitations Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000004855 amber Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000010339 dilation Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000010410 dusting Methods 0.000 description 1
230000005684 electric field Effects 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000002462 imidazolines Chemical class 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
LBEKFAUAYVGHFP-UHFFFAOYSA-N methyl 4-amino-3,5-dichlorobenzoate Chemical compound COC(=O)C1=CC(Cl)=C(N)C(Cl)=C1 LBEKFAUAYVGHFP-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100000017 mucous membrane irritation Toxicity 0.000 description 1
229960005016 naphazoline Drugs 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000002304 perfume Substances 0.000 description 1
229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
231100000901 systemic toxic effect Toxicity 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960000337 tetryzoline Drugs 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
229940100613 topical solution Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
230000003639 vasoconstrictive effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960000833 xylometazoline Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Medicinal Preparation (AREA)

NO864993A 1985-12-11 1986-12-10 2-((3,5-dihalo-4-aminobenzyl))imidazoliner. NO864993L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/807,921 US4665095A (en)	1985-12-11	1985-12-11	Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion

Publications (2)

Publication Number	Publication Date
NO864993D0 NO864993D0 (no)	1986-12-10
NO864993L true NO864993L (no)	1987-06-12

Family

ID=25197433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO864993A NO864993L (no)	1985-12-11	1986-12-10	2-((3,5-dihalo-4-aminobenzyl))imidazoliner.

Country Status (9)

Country	Link
US (1)	US4665095A (fr)
EP (1)	EP0230532B1 (fr)
JP (1)	JPH07116038B2 (fr)
AU (1)	AU591740B2 (fr)
CA (1)	CA1282334C (fr)
DE (1)	DE3674569D1 (fr)
FI (1)	FI865025L (fr)
NO (1)	NO864993L (fr)
NZ (1)	NZ218334A (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5114979A (en) *	1989-10-18	1992-05-19	Schering Corporation	Fruity flavored nasal decongestant composition
US4970240A (en) *	1989-10-18	1990-11-13	Schering Corporation	Fruity flavored nasal decongestant composition
JP4096363B2 (ja) *	1997-03-14	2008-06-04	日本新薬株式会社	鼻又は眼の充血治療剤
SG72827A1 (en) *	1997-06-23	2000-05-23	Hoffmann La Roche	Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
MXPA00010805A (es) *	1998-05-06	2002-05-08	Univ Duke	Metodo para el tratamiento de sindromes de la vejiga y del tracto urinario inferior.
CA2637312A1 (fr) *	2006-01-27	2007-08-02	F. Hoffmann-La Roche Ag	Utilisation de 2-imidazole substitue de derives d'imidazoline
AU2007312389B2 (en) *	2006-10-19	2012-02-23	F. Hoffmann-La Roche Ag	Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
RU2009112496A (ru) *	2006-10-19	2010-11-27	Ф. Хоффманн-Ля Рош Аг (Ch)	Аминометил-4-имидазолы
CA2668454A1 (fr) *	2006-11-02	2008-05-08	F. Hoffmann-La Roche Ag	2-imidazoles substitues en tant que modulateurs des recepteurs associes aux amines de trace
JP2010510184A (ja) *	2006-11-16	2010-04-02	エフ．ホフマン−ラロシュアーゲー	置換４−イミダゾール類
CA2672617A1 (fr) *	2006-12-13	2008-06-19	F. Hoffmann-La Roche Ag	Utilisation de nouveaux 2-imidazoles comme ligands pour recepteurs associes a une amine de trace (taar)
US20080146523A1 (en) *	2006-12-18	2008-06-19	Guido Galley	Imidazole derivatives
CN101600700B (zh) *	2007-02-02	2013-08-21	弗·哈夫曼-拉罗切有限公司	作为taar1配体用于cns病症的新的2-氨基噁唑啉
KR101222412B1 (ko) *	2007-02-15	2013-01-15	에프. 호프만-라 로슈 아게	Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
CN101687812A (zh)	2007-07-02	2010-03-31	弗·哈夫曼-拉罗切有限公司	对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
CA2691704A1 (fr) *	2007-07-03	2009-01-08	F. Hoffmann-La Roche Ag	4-imidazolines et leur utilisation comme antidepresseurs
CA2694362A1 (fr) *	2007-07-27	2009-02-05	F. Hoffmann-La Roche Ag	2-azetidinemethaneamines et 2-pyrrolidinemethaneamines comme ligands de taar
CN101765425A (zh) *	2007-08-02	2010-06-30	弗·哈夫曼-拉罗切有限公司	苯甲酰胺衍生物用于治疗cns障碍的用途
JP5341084B2 (ja) *	2007-08-03	2013-11-13	エフ．ホフマン−ラロシュアーゲー	Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
JP5546455B2 (ja) *	2007-10-02	2014-07-09	リグスホスピタル	交感神経系α‐および／またはβ‐アドレナリン受容体に対してアゴニスト作用を有する交感神経作動薬の血餅強度改善に関連した全身的止血促進効果
CN102083805A (zh) *	2008-07-24	2011-06-01	弗·哈夫曼-拉罗切有限公司	4,5-二氢-唑-2-基衍生物
US8242153B2 (en) *	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
US20100311798A1 (en) *	2009-06-05	2010-12-09	Decoret Guillaume	2-aminooxazolines as taar1 ligands
US8354441B2 (en) *	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
CN108713019B (zh)	2016-03-17	2021-06-15	豪夫迈·罗氏有限公司	具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物
EP4732889A2 (fr)	2017-06-07	2026-04-29	Supira Medical, Inc.	Dispositifs de déplacement de fluide intravasculaire, systèmes et procédés d'utilisation
US11511103B2 (en)	2017-11-13	2022-11-29	Shifamed Holdings, Llc	Intravascular fluid movement devices, systems, and methods of use
JP7410034B2 (ja)	2018-02-01	2024-01-09	シファメド・ホールディングス・エルエルシー	血管内血液ポンプならびに使用および製造の方法
WO2020028537A1 (fr)	2018-07-31	2020-02-06	Shifamed Holdings, Llc	Pompes sanguines intravasculaires et procédés d'utilisation
WO2020073047A1 (fr)	2018-10-05	2020-04-09	Shifamed Holdings, Llc	Pompes à sang intravasculaires et procédés d'utilisation
WO2021011473A1 (fr)	2019-07-12	2021-01-21	Shifamed Holdings, Llc	Pompes à sang intravasculaires et méthode d'utilisation et procédé de fabrication
US11654275B2 (en)	2019-07-22	2023-05-23	Shifamed Holdings, Llc	Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (fr)	2019-08-07	2023-08-30	Calomeni, Michael	Pompes sanguines à cathéter et boîtiers de pompe pliants
EP4034192B1 (fr)	2019-09-25	2025-12-24	Supira Medical, Inc.	Dispositifs et systèmes de pompes à sang intravasculaires et leurs procédés d'utilisation et de commande
WO2021062260A1 (fr)	2019-09-25	2021-04-01	Shifamed Holdings, Llc	Pompes à sang de cathéter et conduits sanguins pliables
EP4034221B1 (fr)	2019-09-25	2024-11-13	Shifamed Holdings, LLC	Pompes à sang de cathéter et boîtiers de pompe pliables
EP4072650A4 (fr)	2019-12-11	2024-01-10	Shifamed Holdings, LLC	Pompes à sang d'aorte descendante et de veine cave
US12599758B2 (en)	2019-12-19	2026-04-14	Shifamed Holdings, Llc	Intravascular blood pumps, motors, and fluid control
EP4204404A4 (fr) *	2020-08-27	2024-12-25	Curasen Therapeutics, Inc.	Agonistes du récepteur alpha1a-adrénergique et méthodes d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2731471A (en) *		1956-01-17		Nxg hi
US2868802A (en) *		1959-01-13		Nxchj
DE1617618B2 (de) *	1966-06-18	1976-05-20	Merck Patent Gmbh, 6100 Darmstadt	Schleimhautabschwellende mittel zur lokalen applikation
DE1618005A1 (de) *	1966-09-22	1971-09-09	Thomae Gmbh Dr K	Verfahren zur Herstellung von neuen Amino-dihalogen-phenyl-aethylaminen
US3660423A (en) *	1970-02-13	1972-05-02	Dow Chemical Co	2-(substituted benzyl)methyl-2-imidazolines
US3922282A (en) *	1975-01-17	1975-11-25	American Home Prod	2-Aryl-2-imidazoline-1-propionic acids and their esters
AU1623483A (en) *	1978-02-01	1983-10-13	Wellcome Foundation Limited, The	Formulations of imidazole derivatives
US4506074A (en) *	1982-11-08	1985-03-19	Merck & Co., Inc.	2-[2-Pyridinyloxy(thio or amino)methyl]-1H-imidazoles and derivatives
US4461914A (en) *	1983-02-01	1984-07-24	American Cyanamid Company	Method for the preparation of 1-(4'-amino-3',5'-dichlorophenyl)-2-alkyl(or dialkyl)aminoethanols
FR2549049B1 (fr) *	1983-07-13	1986-06-20	Chauvin Blache Lab	Nouvelles amidines, leur procede de preparation et leur application therapeutique

1985
- 1985-12-11 US US06/807,921 patent/US4665095A/en not_active Expired - Fee Related
1986
- 1986-10-30 DE DE8686115057T patent/DE3674569D1/de not_active Expired - Fee Related
- 1986-10-30 EP EP86115057A patent/EP0230532B1/fr not_active Expired - Lifetime
- 1986-11-19 NZ NZ218334A patent/NZ218334A/xx unknown
- 1986-11-28 JP JP61282192A patent/JPH07116038B2/ja not_active Expired - Lifetime
- 1986-12-02 CA CA000524368A patent/CA1282334C/fr not_active Expired - Fee Related
- 1986-12-09 AU AU66319/86A patent/AU591740B2/en not_active Ceased
- 1986-12-10 NO NO864993A patent/NO864993L/no unknown
- 1986-12-10 FI FI865025A patent/FI865025L/fi not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO864993D0 (no)	1986-12-10
JPH07116038B2 (ja)	1995-12-13
AU591740B2 (en)	1989-12-14
NZ218334A (en)	1989-03-29
FI865025A7 (fi)	1987-06-12
EP0230532B1 (fr)	1990-09-26
FI865025A0 (fi)	1986-12-10
AU6631986A (en)	1987-06-18
JPS62145067A (ja)	1987-06-29
US4665095A (en)	1987-05-12
EP0230532A1 (fr)	1987-08-05
DE3674569D1 (de)	1990-10-31
FI865025L (fi)	1987-06-12
CA1282334C (fr)	1991-04-02

Publication	Publication Date	Title
NO864993L (no)	1987-06-12	2-((3,5-dihalo-4-aminobenzyl))imidazoliner.
RU2491072C2 (ru)	2013-08-27	Композиции для лечения легочной гипертензии, вводимые путем ингаляции, и способы их применения
US5096916A (en)	1992-03-17	Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
JP6045495B2 (ja)	2016-12-14	眼圧を低下させるための［３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル］メタノールのエステル・プロドラッグ
CS253702B2 (en)	1987-12-17	Process for preparing new 3-/1-imidazolylalkyl/indoles
CH644597A5 (de)	1984-08-15	Imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
Kollias‐Baker et al.	1993	Influence of yohimbine and tolazoline on the cardiovascular, respiratory, and sedative effects of xylazine in the horse
WO1989005294A1 (fr)	1989-06-15	Quinoleines substituees
JPH0545584B2 (fr)	1993-07-09
NZ238964A (en)	1992-06-25	Geometrically and optically pure 1r-cis,1'r-cis atracurium salts, preparation and pharmaceutical compositions thereof
SK147994A3 (en)	1995-07-11	The sulphate salt of a substituted triazole, pharmaceutical composition thereof, and their use in therapy
US5250286A (en)	1993-10-05	Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
KR20230058066A (ko)	2023-05-02	α1A-아드레날린성 수용체 작용제 및 사용 방법
SK68599A3 (en)	2000-06-12	Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
JP4096363B2 (ja)	2008-06-04	鼻又は眼の充血治療剤
JPH05500060A (ja)	1993-01-14	置換キノリン類
US3424843A (en)	1969-01-28	Composition and methods for controlling hypertension with 2-azidoacetophenone oxime
JPS5883626A (ja)	1983-05-19	抗炎症剤
JPS6360743B2 (fr)	1988-11-25